Top Research Reports for Verizon, The Southern Co. & Blackstone
Research Reports Overview: Zacks Research Daily features reports on 16 major stocks, including Verizon, Southern Company, and Blackstone, highlighting their performance, market challenges, and growth prospects, particularly in sectors like wireless technology and clean energy.
Market Insights: The "Ahead of Wall Street" article provides investors with insights into economic releases affecting market actions, while the ongoing tariff saga impacts pre-market trading negatively.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on UTMD
About UTMD
About the author
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
